Glaxosmithkline Pharmaceuticals Ltd
Glaxosmithkline Pharmaceuticals Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Guidance rank: #64 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Glaxosmithkline Pharmaceuticals Ltd Q2 FY27 key numbers
- Revenue
- Standalone revenue from operations for Q2 was Rs. 117,991 lakhs versus Rs. 97,363 lakhs in Q2 2025, a rise of about 21.2% year-on-year.
As stated in Glaxosmithkline Pharmaceuticals Ltd's Q2 FY27 results statement · published 3 Nov 2026. Reported figures, not investment advice.
Based on Glaxosmithkline Pharmaceuticals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
For Q2 (3 months ended 30.09.2026), consolidated revenue from operations was Rs. 118,357 lakhs, up from Rs. 97,994 lakhs in the corresponding quarter of 2025, reflecting a year-on-year increase of app. Quarterly Financials (Q2 ended 30.09.2026):.
From Glaxosmithkline Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.
How did Glaxosmithkline Pharmaceuticals' revenue grow in the September 2026 quarter?
- For Q2 (3 months ended 30.09.2026), consolidated revenue from operations was Rs. 118,357 lakhs, up from Rs. 97,994 lakhs in the corresponding quarter of 2025, reflecting a year-on-year increase of approximately 20.8%.
- Standalone revenue from operations for Q2 was Rs. 117,991 lakhs versus Rs. 97,363 lakhs in Q2 2025, a rise of about 21.2% year-on-year.
- The consolidated total income (including other income) was Rs. 125,635 lakhs in Q2 2026 compared to Rs. 101,351 lakhs in Q2 2025.
What happened to Glaxosmithkline Pharmaceuticals' margins in Q2 FY27?
See what Glaxosmithkline Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
What capex is Glaxosmithkline Pharmaceuticals planning?
2 more points from Glaxosmithkline Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Glaxosmithkline Pharmaceuticals raising money or cutting debt?
See what Glaxosmithkline Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Glaxosmithkline Pharmaceuticals' order book?
- It contains the independent auditor’s review reports, statement of cash flows, statement of assets and liabilities, earnings per share, and other financial disclosures.
- The focus is on revenue, profit, income, expenses, and compliance-related updates (such as change in senior management and auditors).
- There is no reference to order books, order inflows, or pending orders in any sections or notes of the provided presentation pages.
Glaxosmithkline Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.2K Cr, net profit ₹336 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Glaxosmithkline Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lupin (Q2 FY27)
Q2 FY27 Net Sales: ₹77,855 million, up 14.0% YoY (Page 13) . Key investor presentation takeaways from Lupin Ltd's Q2 FY27 investor presentation — and how it ran
- Remus Pharmaceuticals (Q2 FY27)
Standalone Revenue (H1 FY27 vs H1 FY26):** ₹62.08 Cr vs ₹46.85 Cr, growth of 32.51% . Key results statement takeaways from Remus Pharmaceuticals Ltd's Q2 FY27 e
- Amrutanjan Healt (Q2 FY27)
Q2 FY27 Net Sales:** ₹135.18 Crores, up 14.85% YoY (₹117.70 Crores in Q2 FY26) . Key investor presentation takeaways from Amrutanjan Health Care Ltd's Q2 FY27 i
- Pfizer (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026: ₹726.86 crore (Page 3). Key results statement takeaways from Pfizer Ltd's Q2 FY27 results stat
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Glaxosmithkline Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Glaxosmithkline Pharmaceuticals Ltd Q2 FY27 results?
For Q2 (3 months ended 30.09.2026), consolidated revenue from operations was Rs. 118,357 lakhs, up from Rs. 97,994 lakhs in the corresponding quarter of 2025, reflecting a year-on-year increase of app. Quarterly Financials (Q2 ended 30.09.2026):.
What is Glaxosmithkline Pharmaceuticals Ltd share price analysis?
Glaxosmithkline Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 41.4 with a market cap of ₹43,624 Cr. Investors should review the full earnings analysis for detailed insights.
Is Glaxosmithkline Pharmaceuticals Ltd planning capital expenditure?
The presentation indications of capex, capacity expansion, or new projects based on the provided pages are:.
Keep Glaxosmithkline Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.